AstraZeneca PLC
02 April 2007
Dealing by Directors
Companies Act 1985 Sections 324/329
Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rules DR 3.1.2R
We hereby inform you that on 30 March 2007 the following Directors of
AstraZeneca PLC were each granted an award under the terms of the AstraZeneca
Performance Share Plan over the Company's USD0.25 Ordinary Shares.
Target number of Award price Total interest in Percentage of
shares awarded per share Normal vesting shares after this shares in issue
date award
Name of Director
D R Brennan 107,051 2744p 30 March 2007 See below See below
J R Symonds 50,291 2744p 30 March 2007 165,212 0.010%
J S Patterson 36,785 2744p 30 March 2007 131,287 0.009%
The AstraZeneca Performance Share Plan was approved by shareholders at the
Company's AGM in 2005. Awards made under the Plan may not generally vest before
the third anniversary of the relevant date of grant nor unless the specified
performance target(s) have been met at the end of the three year period which,
for this award, is 1 January 2007 to 31 December 2009.
The performance target that applies to this award is the Company's Total
Shareholder Return ('TSR') compared to the TSR of a selected peer group of 12
other pharmaceutical companies. The actual number of shares to which a
participant may become unconditionally entitled will depend on the extent to
which the performance target(s) have been met. A summary of the Plan, including
a more detailed explanation of the performance target(s), can be found in the
AstraZeneca Annual Report and Form 20-F Information 2006 which is available on
the Company's website www.astrazeneca.com.
Mr Brennan has interests in the Company's Ordinary Shares and American
Depositary Shares (ADSs). One ADS equals one Ordinary Share. In total, Mr
Brennan now has an interest in 217,618 Ordinary Shares and 140,803 ADSs which
together represent approximately 0.024% of the number of shares currently in
issue.
G H R Musker
Company Secretary
2 April 2007
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.